We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01770613
Recruitment Status : Withdrawn (Corporate business decision, may consider different subject population)
First Posted : January 18, 2013
Last Update Posted : April 27, 2017
CardioCell LLC
Information provided by (Responsible Party):
Stemedica Cell Technologies, Inc.

Brief Summary:
The purpose of this study is to assess the safety and tolerability of human allogeneic mesenchymal bone marrow cells (aMBMC) administered intravenously to subjects with ST Segment Elevation Myocardial Infarction (STEMI).

Condition or disease Intervention/treatment Phase
ST Segment Elevation Myocardial Infarction (STEMI) Allogeneic Mesenchymal Bone Marrow Cells Biological: Stem cells Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : February 2013
Estimated Primary Completion Date : May 2016
Estimated Study Completion Date : May 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Arm Intervention/treatment
Experimental: Stem Cells
Biological: Stem cells
Allogeneic mesenchymal stem cells

Placebo Comparator: Control
Lactated Ringer's Solution
Biological: Stem cells
Allogeneic mesenchymal stem cells

Primary Outcome Measures :
  1. The safety and tolerability of aMBMC intravenous administration during the twelve month study period as determined by major adverse events MACE endpoint. [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. The change from baseline on physical exam conducted at day 14 and at 1, 3, 6 and 12 months post-administration, as available: [ Time Frame: 12 months ]
  2. • LV end diastolic volume [ Time Frame: 12 months ]
  3. • LV end systolic volume [ Time Frame: 12 months ]
  4. • Infarct size measured by MRI, with and without contrast (only for patients eligible for MRI) [ Time Frame: 12 months ]
  5. • Global Left Ventricular Ejection Fraction (measured by echocardiography) [ Time Frame: 12 months ]
  6. • SF-36 Health Assessment [ Time Frame: 12 months ]
  7. • Incidence of Ventricular Arrhythmias requiring intervention at 1 and 3 months post-administration [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males and females 18-85 years of age.
  2. First ST Segment Elevation Myocardial Infarction (STEMI) of ischemic etiology affecting the left ventricle within 7 days of study enrollment. Myocardial infarction is defined as ECG evidence of clinically significant ST-segment elevation (>1mm [0.1 mV] in at least 2 contiguous precordial leads or in at least 2 adjacent limb leads).
  3. Subject had successful revascularization within 12 hours of symptoms as evidenced by residual stenosis < 30% and TIMI antegrade flow II or III in the culprit vessel. Revascularization may include one of the following:

    • PCI angioplasty/stenting placement
    • Thrombolytic therapy
  4. LVEF ≤45% as determined by 16-lead quantitative 2D echocardiography more than 24 hours after revascularization.
  5. Life expectancy greater than 12 months.
  6. Ability to understand and provide signed informed consent, or have a designated legal guardian or spouse legally able and willing to make such decisions on the subject's behalf.
  7. Reasonable expectation that subject will receive standard post myocardial infarction care, unless contraindicated, including medications:

    • Anticoagulation (e.g. aspirin, clopidogrel, ticlopidine, prasugrel, etc.), beta-blockers, ace inhibitors, and statin agents, as tolerated.

  8. Attend all scheduled safety follow-up visits.

Exclusion Criteria:

  1. Hemodynamic instability as demonstrated by any of the following:

    1. Requirement of intra-aortic balloon pump of left ventricular assist device.
    2. Need for inotropic support (e.g. dopamine and/or dobutamine) for more than 36 hours for the maintenance of mean arterial blood pressure ≥60 mmHg.
  2. History of cancer within the past 5 years, with the exception of localized basal or squamous cell carcinoma.
  3. Clinically-significant hematologic, hepatic, or renal impairment within 24 hours of study procedure as determined by screening clinical laboratory tests. Severe chronic anemia or hematocrit ≤24%. Liver function tests (total bilirubin at 3 times upper limit of normal, or creatinine level ≥3mg/dL).
  4. Presence of any other clinically-significant medical condition, psychiatric condition, or laboratory abnormality, that in the judgment of the Investigator or Sponsor for which participation in the study would pose a safety risk to the subject.
  5. Participation in another study with an investigational drug or device within 3 months prior to stem cell administration.
  6. History within the past year of drug or alcohol abuse.
  7. Females known to be pregnant, lactating or having a positive pregnancy test (will be tested during screening) or planning to become pregnant during the study.
  8. Inability to comply with the conditions of the protocol.
  9. Presence of a transplanted tissue or organ or left ventricular assist device (LVAD) (or the expectation of the same within the next 12 months).
  10. Planned Automatic Implantable Cardiac Defibrillator (AICD) or CRT within the next 12 months.
  11. Need for chronic intermittent inotropic therapy.
  12. Active myocarditis or early postpartum cardiomyopathy (within the first twelve months of delivery).
  13. Systemic corticosteroids, cytostatics, immunosuppressive drug therapy (cyclophosphamide, methotrexate, cyclosporine, azathioprine, etc.), and DNA depleting or cytotoxic drugs taken within four weeks prior to study stem cell administration.
  14. Porphyria.
  15. Allergy to sodium citrate or any "caine" type of local anesthetic.
  16. Subject scheduled for hospice care.
  17. Clinically relevant abnormal findings in the clinical history, physical examination, ECG (e.g. life threatening arrhythmias, including QTc interval of ≥550 ms) or laboratory tests at the screening assessment that would interfere with the objectives of the study or that would, in the Investigator's opinion, preclude safe completion of the study.
  18. Abnormal findings could include: known HIV infection or other immunodeficiency state, chronic active viral infection (such as hepatitis B or C), acute systemic infections (defined as subjects undergoing treatment with antibiotics), gastrointestinal tract bleeding, or any severe or acute concomitant illness or injury.
  19. Any other medical, social, or geographical factor that would make it unlikely that the subject could comply with study procedures (e.g., alcohol abuse, lack of permanent residence, severe depression, disorientation, distant location, or a history of noncompliance).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01770613

Layout table for location information
United States, Arizona
Mercy Gilbert and Chandler Medical Center
Gilbert, Arizona, United States, 85224
United States, Georgia
Emory University Hospital
Atlanta, Georgia, United States, 30033
Sponsors and Collaborators
Stemedica Cell Technologies, Inc.
CardioCell LLC
Layout table for investigator information
Principal Investigator: Nabil Dib, MD, MSc, FACC Mercy Gilbert Medical Center, Dignity Health
Layout table for additonal information
Responsible Party: Stemedica Cell Technologies, Inc.
ClinicalTrials.gov Identifier: NCT01770613    
Other Study ID Numbers: STEM 103-M-STEMI
First Posted: January 18, 2013    Key Record Dates
Last Update Posted: April 27, 2017
Last Verified: April 2017
Keywords provided by Stemedica Cell Technologies, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Infarction
ST Elevation Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases